Edwards Lifesciences To Present At The UBS Warburg Global Life Sciences Conference

IRVINE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation , a world leader in products and technologies to treat advanced cardiovascular disease, is scheduled to participate in the UBS Global Life Sciences Conference at The Grand Hyatt Hotel in New York on Tuesday, September 26, 2006.

Michael A. Mussallem, Edwards Lifesciences' chairman and chief executive officer, is scheduled to speak to conference attendees at 8:00 a.m. ET. A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences' investor relations website at http://www.edwards.com/InvestorRelations/EventCalendar.htm. An archived version of the webcast will be available later that day on the Edwards' investor relations website in the News and Events section.

About Edwards Lifesciences

Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna, and Swan-Ganz. Additional company information can be found at http://www.edwards.com.

Edwards, FloTrac, and Magna are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.

Edwards Lifesciences Corporation

CONTACT: Media, Jared B. Adams, +1-949-250-5070, or Investors, David K.Erickson, +1-949-250-6826, both of Edwards Lifesciences

MORE ON THIS TOPIC